Kyntheum (Brodalumab)

Brodalumab is a fully human monoclonal antibody that binds to the interleukin‑17 receptor A (IL‑17RA) on immune and skin cells. By blocking this receptor, it prevents signaling from several IL‑17 cytokines, inhibiting downstream inflammatory pathways such as NF‑κB and MAPK. This suppression reduces the inflammatory response that drives psoriasis lesions.

The specific dose and dosing schedule of Kyntheum are determined by the prescribing physician based on the patient’s clinical condition, weight, and response to therapy. The medication is supplied as a 210 mg/1 mL solution for subcutaneous injection, and the healthcare provider will outline the exact regimen and frequency.

The safety of brodalumab in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the drug is generally avoided in pregnant or nursing women unless the potential benefit justifies the potential risk. Women of childbearing potential should discuss contraception and pregnancy planning with their healthcare provider before starting therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Kyntheum. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, cold‑chain shipping details and assists with any necessary import documentation.

Kyntheum (brodalumab) differs from other biologics such as secukinumab or ixekizumab by targeting the IL‑17 receptor rather than the IL‑17 cytokine itself. This broader blockade may offer efficacy in patients who have not responded adequately to other IL‑17 inhibitors. However, therapeutic choice depends on individual patient factors, safety profile, and physician judgment.

Kyntheum must be stored refrigerated at 2–8 °C (36–46 °F). It should be kept in its original carton to protect from light, and must not be frozen or shaken. Prior to administration, the solution should be inspected for particulate matter and used within the time frame specified by the manufacturer after removal from refrigeration.

Kyntheum is supplied as a sterile solution for injection and is administered subcutaneously by a qualified healthcare professional. The injection is typically given in the abdomen, thigh, or upper arm. Proper aseptic technique and the correct dosing as prescribed are essential to ensure efficacy and minimize injection‑site reactions.

The most serious risks include the potential for suicidal ideation or behavior, serious infections such as pneumonia or cellulitis, and neutropenia which can increase susceptibility to infections. Patients should be monitored closely for any signs of mood changes, infection, or abnormal blood counts, and any concerning symptoms should prompt immediate medical evaluation.

Kyntheum is contraindicated in patients with known hypersensitivity to brodalumab or any component of the formulation. It should also be avoided in individuals with active serious infections, uncontrolled inflammatory bowel disease, or those who are pregnant or breastfeeding unless the benefits outweigh the risks. A thorough medical assessment by a healthcare provider is required before initiating therapy.